UK Markets close in 7 hrs 21 mins
  • FTSE 100

    7,119.04
    +9.07 (+0.13%)
     
  • FTSE 250

    22,490.26
    -19.86 (-0.09%)
     
  • AIM

    1,240.16
    +1.68 (+0.14%)
     
  • GBP/EUR

    1.1636
    -0.0028 (-0.24%)
     
  • GBP/USD

    1.3897
    -0.0024 (-0.1751%)
     
  • BTC-GBP

    24,548.61
    +731.32 (+3.07%)
     
  • CMC Crypto 200

    819.41
    +32.80 (+4.17%)
     
  • S&P 500

    4,266.49
    +24.65 (+0.58%)
     
  • DOW

    34,196.82
    +322.58 (+0.95%)
     
  • CRUDE OIL

    73.53
    +0.23 (+0.31%)
     
  • GOLD FUTURES

    1,782.70
    +6.00 (+0.34%)
     
  • NIKKEI 225

    29,066.18
    +190.95 (+0.66%)
     
  • HANG SENG

    29,286.03
    +403.57 (+1.40%)
     
  • DAX

    15,576.69
    -12.54 (-0.08%)
     
  • CAC 40

    6,625.91
    -5.24 (-0.08%)
     

Auris Medical Holding to Present at LD Micro Invitational XI Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.

About Auris Medical

Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne viruses and allergens BentrioTM (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Investor contact:

investors@aurismedical.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting